Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 5
Neuropsychiatric Disease and Treatment
ISSN: 1178-2021
- View all (4094)
- Volume 19, 2023 (237)
- Volume 18, 2022 (272)
- Volume 17, 2021 (351)
- Volume 16, 2020 (325)
- Volume 15, 2019 (353)
- Volume 14, 2018 (354)
- Volume 13, 2017 (333)
- Volume 12, 2016 (367)
- Volume 11, 2015 (340)
- Volume 10, 2014 (275)
- Volume 9, 2013 (223)
- Volume 8, 2012 (74)
- Volume 7, 2011 (87)
- Volume 6, 2010 (90)
- Volume 5, 2009 (65)
- Volume 4, 2008 (128)
- Volume 3, 2007 (105)
- Volume 2, 2006 (70)
- Volume 1, 2005 (45)
Archive: Volume 5, 2009
Clinical features of adolescents with deliberate self-harm: A case control study in Lisbon, Portugal
Diogo F Guerreiro, Ema L Neves, Rita Navarro, et al
Neuropsychiatric Disease and Treatment 2009, 5:611-617
Published Date: 12 November 2009
Coenzyme Q10 effects in neurodegenerative disease
Meredith Spindler, M Flint Beal, Claire Henchcliffe
Neuropsychiatric Disease and Treatment 2009, 5:597-610
Published Date: 9 November 2009
Current and emerging treatments for amyotrophic lateral sclerosis
Stefano Zoccolella, Andrea Santamato, Paolo Lamberti
Neuropsychiatric Disease and Treatment 2009, 5:577-595
Published Date: 3 November 2009
Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults
Robert H Howland
Neuropsychiatric Disease and Treatment 2009, 5:563-576
Published Date: 3 November 2009
Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease
Umamon Puangthong, Ging-Yuek Robin Hsiung
Neuropsychiatric Disease and Treatment 2009, 5:553-561
Published Date: 30 October 2009
Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide
Carl E Stafstrom
Neuropsychiatric Disease and Treatment 2009, 5:547-551
Published Date: 23 October 2009
Psychological and behavioral disease during developmental age: the importance of the alliance with parents
Michela Gatta, Elisabetta Ramaglioni, Jessica Lai, et al.
Neuropsychiatric Disease and Treatment 2009, 5:541-546
Published Date: 22 October 2009
Sleep disorders in Parkinson’s disease
Israt Jahan, Robert A Hauser, Kelly L Sullivan, Amber Miller, et al.
Neuropsychiatric Disease and Treatment 2009, 5:535-540
Published Date: 15 October 2009
Neuropsychological effects of antiepileptic drugs (carbamazepine versus valproate) in adult males with epilepsy
Ghaydaa A Shehata, Abd El-aziz M Bateh, Sherifa A Hamed, et al
Neuropsychiatric Disease and Treatment 2009, 5:527-533
Published Date: 15 October 2009
Late- versus early-onset geriatric depression in a memory research center
Carol Dillon, Ricardo F Allegri, Cecilia M Serrano, et al
Neuropsychiatric Disease and Treatment 2009, 5:517-526
Published Date: 9 October 2009
Treatment of refractory complex partial seizures: role of vigabatrin
Elizabeth J Waterhouse, Kimberly N Mims, Soundarya N Gowda
Neuropsychiatric Disease and Treatment 2009, 5:505-515
Published Date: 6 October 2009
A qualitative motion analysis study of voluntary hand movement induced by music in patients with Rett syndrome
Tohshin Go, Asako Mitani
Neuropsychiatric Disease and Treatment 2009, 5:499-503
Published Date: 2 October 2009
Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
Xinhua S Ren, Lawrence Herz, Shirley Qian, et al
Neuropsychiatric Disease and Treatment 2009, 5:491-498
Published Date: 30 September 2009
Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder
Delia Bishara, David Taylor
Neuropsychiatric Disease and Treatment 2009, 5:483-490
Published Date: 21 September 2009
Body dysmorphic disorder: A complex and polymorphic affection
Patrizia Fiori, Luigi Maria Giannetti
Neuropsychiatric Disease and Treatment 2009, 5:477-481
Published Date: 9 September 2009
Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures
Carol M Ulloa, Allen Towfigh, Joseph Safdieh
Neuropsychiatric Disease and Treatment 2009, 5:467-476
Published Date: 11 September 2009
Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder
Jan K Buitelaar, J Antoni Ramos-Quiroga, Miguel Casas, et al
Neuropsychiatric Disease and Treatment 2009, 5:457-466
Published Date: 24 August 2009
Computerized assessment of pain drawing area: A pilot study
Anna Wenngren, Britt-Marie Stålnacke
Neuropsychiatric Disease and Treatment 2009, 5:451-456
Published Date: 20 August 2009
Brain-derived neurotrophic factor: role in depression and suicide
Yogesh Dwivedi
Neuropsychiatric Disease and Treatment 2009, 5:433-449
Published Date: 17 August 2009
Management of attention-deficit hyperactivity disorder in adults: focus on methylphenidate hydrochloride
Rajasree Nair, Shannon B Moss
Neuropsychiatric Disease and Treatment 2009, 5:421-432
Published Date: 10 August 2009
Effect of milnacipran on suicidality in patients with mild to moderate depressive disorder
Alla Avedisova, Vladimir Borodin, Ksenia Zakharova, et al
Neuropsychiatric Disease and Treatment 2009, 5:415-420
Published Date: 31 July 2009
Pregabalin in the management of partial epilepsy
Amir M Arain
Neuropsychiatric Disease and Treatment 2009, 5:407-413
Published Date: 31 July 2009
Who coined the term “status gelasticus”? We did
Yu-tze Ng
Neuropsychiatric Disease and Treatment 2009, 5:405-406
Published Date: 16 July 2009
Clinical characteristics and long-term response to mood stabilizers in patients with bipolar disorder and different age at onset
Bernardo Dell’Osso, Massimiliano Buoli, Riccardo Riundi, Nazario D’Urso, et al.
Neuropsychiatric Disease and Treatment 2009, 5:399-404
Published Date: 14 July 2009
Influence of serotonergic/noradrenergic gene polymorphisms on nausea and sweating induced by milnacipran in the treatment of depression
Hisashi Higuchi, Hitoshi Takahashi, Mitsuhiro Kamata, Keizo Yoshida
Neuropsychiatric Disease and Treatment 2009, 5:393-398
Published Date: 14 July 2009
Treatment of obese patients with binge eating disorder using topiramate: a review
Paolo Leombruni, Luca Lavagnino, Secondo Fassino
Neuropsychiatric Disease and Treatment 2009, 5:385-392
Published Date: 7 July 2009
Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues
William V Bobo, Richard C Shelton
Neuropsychiatric Disease and Treatment 2009, 5:369-383
Published Date: 1 July 2009
Adenylate-cyclase activity in platelets of patients with obsessive-compulsive disorder
D Marazziti, S Baroni, L Palego, I Masala, G Consoli, M Catena Dell’Osso, G Giannaccini, A Lucacchini
Neuropsychiatric Disease and Treatment 2009, 5:363-367
Published Date: 1 July 2009
Imitation and communication skills development in children with pervasive developmental disorders
Andrea De Giacomo, Claudia Portoghese, Domenico Martinelli, Isabella Fanizza, et al.
Neuropsychiatric Disease and Treatment 2009, 5:355-362
Published Date: 18 June 2009
New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists
Rüdiger Hardeland
Neuropsychiatric Disease and Treatment 2009, 5:341-354
Published Date: 10 June 2009
Review of teriflunomide and its potential in the treatment of multiple sclerosis
Clemens Warnke, Gerd Meyer zu Hörste, Hans-Peter Hartung, Olaf Stüve, et al.
Neuropsychiatric Disease and Treatment 2009, 5:333-340
Published Date: 27 May 2009
A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease
Paul Shotbolt, Michael Samuel, Chris Fox, Anthony S David
Neuropsychiatric Disease and Treatment 2009, 5:327-332
Published Date: 25 May 2009
Frontal brain dysfunction in alcoholism with and without antisocial personality disorder
Marlene Oscar-Berman, Mary M Valmas, Kayle s Sawyer, Shalene M Kirkley, et al.
Neuropsychiatric Disease and Treatment 2009, 5:309-326
Published Date: 25 May 2009
Management of obsessive-compulsive disorder with fluvoxamine extended release
Lídia Ordacgi, Mauro V Mendlowicz, Leonardo F Fontenelle
Neuropsychiatric Disease and Treatment 2009, 5:301-308
Published Date: 26 May 2009
Current trends in the treatment of infantile spasms
Chang-Yong Tsao
Neuropsychiatric Disease and Treatment 2009, 5:289-299
Published Date: 19 May 2009
Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole
David J Muzina
Neuropsychiatric Disease and Treatment 2009, 5:279-288
Published Date: 19 May 2009
Update on the management of symptoms in schizophrenia: focus on amisulpride
Ann M Mortimer
Neuropsychiatric Disease and Treatment 2009, 5:267-277
Published Date: 18 May 2009
Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group)
Heidemarie Abrahamian, Peter Hofmann, Rudolf Prager, Hermann Toplak
Neuropsychiatric Disease and Treatment 2009, 5:261-266
Published Date: 8 May 2009
Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature
Gaetano Zaccara, Luigi M Specchio
Neuropsychiatric Disease and Treatment 2009, 5:249-259
Published Date: 28 April 2009
Update on the use of memantine in Alzheimer’s disease
Robert J van Marum
Neuropsychiatric Disease and Treatment 2009, 5:237-247
Published Date: 12 March 2009
Both stimulatory and inhibitory effects of dietary 5-hydroxytryptophan and tyrosine are found on urinary excretion of serotonin and dopamine in a large human population
George J Trachte, Thomas Uncini, Marty Hinz
Neuropsychiatric Disease and Treatment 2009, 5:227-235
Published Date: 24 April 2009
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
Paul Hammerness, Katherine McCarthy, Elizabeth Mancuso, Cassandra Gendron, Daniel Geller
Neuropsychiatric Disease and Treatment 2009, 5:215-226
Published Date: 25 March 2009
SAFA: A new measure to evaluate psychiatric symptoms detected in a sample of children and adolescents affected by eating disorders. Correlations with risk factors
Emilo Franzoni, Morena Monti, Alessandro Pellicciari, Carlo Muratore, Alberto Verrotti, et al
Neuropsychiatric Disease and Treatment 2009, 5:207-214
Published Date: 19 March 2009
Electroencephalographic and behavioral convulsant effects of hydrobromide and hydrochloride salts of bupropion in conscious rodents
David C Henshall, Nick Dürmüller, H Steve White, Robert Williams, et al.
Neuropsychiatric Disease and Treatment 2009, 5:189-206
Published Date: 12 March 2009
Electrode displacement after intracerebral hematoma as a complication of a deep brain stimulation procedure
Domenico Servello, Marco Sassi, Stefano Bastianello, Guy Umberto Poloni, et al.
Neuropsychiatric Disease and Treatment 2009, 5:183-187
Published Date: 10 March 2009
Psychopharmacology of ADHD in pediatrics: current advances and issues
Donald E Greydanus, Ahsan Nazeer, Dilip R Patel
Neuropsychiatric Disease and Treatment 2009, 5:171-181
Published Date: 5 March 2009
Association of PDE11A global haplotype with major depression and antidepressant drug response
Huai-Rong Luo, Gui-Sheng Wu, Chuanhui Dong, Mauricio Arcos-Burgos, et al.
Neuropsychiatric Disease and Treatment 2009, 5:163-170
Published Date: 10 March 2009
Effects of melatonin in experimental stroke models in acute, sub-acute, and chronic stages
Hsiao-Wen Lin, E-Jian Lee
Neuropsychiatric Disease and Treatment 2009, 5:157-162
Published Date: 10 March 2009
Differential clinical effects of fluvoxamine by the effect of age in Japanese female major depressive patients
Hisashi Higuchi, Kazuhiro Sato, Shingo Naito, Keizo Yoshida, Hitoshi Takahashi, et al
Neuropsychiatric Disease and Treatment 2009, 5:151-155
Published Date: 26 February 2009
Adult ADHD and comorbid depression: A consensus-derived diagnostic algorithm for ADHD
Diane McIntosh, Stan Kutcher, Carin Binder, Anthony Levitt, Angelo Fallu, et al
Neuropsychiatric Disease and Treatment 2009, 5:137-150
Published Date: 5 March 2009
Desvenlafaxine in the treatment of major depressive disorder
Maria Teresa C Lourenco1, Sidney H Kennedy1,2
Neuropsychiatric Disease and Treatment 2009, 5:127-136
Published Date: 19 February 2009
A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole
Salvatore Gentile
Neuropsychiatric Disease and Treatment 2009, 5:117-125
Published Date: 19 February 2009
Cognitive impairment after cerebrovascular stroke: Relationship to vascular risk factors
Eman M Khedr, Sherifa A Hamed, Hala K El-Shereef, Ola A Shawky, Khalid A Mohamed, et al
Neuropsychiatric Disease and Treatment 2009, 5:103-116
Published Date: 15 February 2009
Combination therapy or monotherapy for the depressed type of schizoaffective disorder
Lubomira Izáková, Ivan Andre, Angelos Halaris
Neuropsychiatric Disease and Treatment 2009, 5:91-101
Published Date: 9 February 2009
Postulated vasoactive neuropeptide immunopathology affecting the blood–brain/blood–spinal barrier in certain neuropsychiatric fatigue-related conditions: A role for phosphodiesterase inhibitors in treatment?
Donald R Staines, Ekua W Brenu, Sonya Marshall-Gradisnik
Neuropsychiatric Disease and Treatment 2009, 5:81-89
Published Date: 30 October 2008
Restless legs syndrome: differential diagnosis and management with rotigotine
Giovanni Merlino, Anna Serafini, Francesca Robiony, Mariarosaria Valente, Gian Luigi Gigli
Neuropsychiatric Disease and Treatment 2009, 5:67-80
Published Date: 21 January 2009
Excited delirium: Consideration of selected medical and psychiatric issues
Edith Samuel, Robert B Williams, Richard B Ferrell
Neuropsychiatric Disease and Treatment 2009, 5:61-66
Published Date: 21 January 2009
Ceruloplasmin and superoxide dismutase (SOD1) in heterozygotes for Wilson disease: A case control study
Gudlaug Tórsdóttir, Grétar Gudmundsson, Jakob Kristinsson, Jón Snaedal, Torkell Jóhannesson
Neuropsychiatric Disease and Treatment 2009, 5:55-59
Published Date: 6 March 2009
Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone
Hong Liu-Seifert, Bruce J Kinon, Christopher J Tennant, Jennifer Sniadecki, Jan Volavka
Neuropsychiatric Disease and Treatment 2009, 5:47-54
Published Date: 22 January 2009
Emerging treatments for premature ejaculation: focus on dapoxetine
Wayne JG Hellstrom
Neuropsychiatric Disease and Treatment 2009, 5:37-46
Published Date: 21 December 2008
Update on ropinirole in the treatment of Parkinson’s disease
Holly A Shill, Mark Stacy
Neuropsychiatric Disease and Treatment 2009, 5:33-36
Published Date: 21 December 2008
Duloxetine for the treatment of generalized anxiety disorder: a review
Ahsan Y Khan, Matthew Macaluso
Neuropsychiatric Disease and Treatment 2009, 5:23-31
Published Date: 18 December 2008
Neonatal bilateral lidocaine administration into the ventral hippocampus caused postpubertal behavioral changes: An animal model of neurodevelopmental psychopathological disorders
Vanessa Blas-Valdivia, Edgar Cano-Europa, Adelaida Hernández-García, Rocio Ortiz-Butrón
Neuropsychiatric Disease and Treatment 2009, 5:15-22
Published Date: 2 December 2008
Proinflammatory cytokines differentially influence adult hippocampal cell proliferation depending upon the route and chronicity of administration
Julie Anne Seguin, Jordan Brennan, Emily Mangano, Shawn Hayley
Neuropsychiatric Disease and Treatment 2009, 5:5-14
Published Date: 2 December 2008
Aripiprazole in the treatment of Huntington’s disease: a case series
Andrea Ciammola, Jenny Sassone, Clarissa Colciago, Niccolò E Mencacci, Barbara Poletti, et al
Neuropsychiatric Disease and Treatment 2009, 5:1-4
Published Date: 25 November 2008